References
- AnandBGaletovicAHow market smarts can protect property rightsHarv Bus Rev20048212727915605567
- JohnJFData exclusivity – the generics market’s third hurdleIMS Health200117102021 Available from: http://omaha.sanofi.com/Images/22810_20F_2010.pdfAccessed June 30, 2015
- CrowneEAMihalceanuCInnovators and generics: proposals for balancing pharmaceutical patent protection and public access to cheaper medicines in CanadaIDEA201151693 Available from: http://ssrn.com/abstract=1665342Accessed June 30, 2015
- Costa-FontJBurakoffAOverview of progress in the international regulation of the pharmaceutical industryPierce L Rev20021103
- KaraWFood and drug law as intellectual property law: historical reflectionsWis L Rev201112331352
- BaiTChenJShiLWAnalysis of the protection to marketing approval data under the TRIPS AgreementChin J New Drugs2009181918231826
- LiuJJYangYStudy on improving the data protection system in ChinaChin J New Drugs201221169
- ZhangXMQiuJXDiscussion on development of drug data protection in ChinaChina Pharm200516211607
- ChenYLiJLiJAKnowledge representation method for pharmaceutical products in ChinaMod Lib Infor20132346915
- OhlyDCPatelSKThe Hatch-Waxman act: prescriptions for innovative and inexpensive medicinesU Balt Intell Prop LJ201119107179 Available from: http://www.schiffhardin.com/Templates/Media/files/publications/PDF/ohly-Hatch_Waxman_Prescriptions-42010.pdfAccessed June 30, 2015
- ParkSDrug approval-patent linkage systems in the US and CanadaJ Kor Pharm Sci200838207
- ShreyaMDo developing countries need a pharmaceutical data-exclusivity regime?Eur Intellect Prop Rev2010326268273
- MillerJSJoint defense or research joint venture? Reassessing the patent-challenge-bloc’s antitrust statusStan Tech L Rev20113512
- GalbraithCDDying to know: a demand for genuine public access to clinical trial results dataMiss LJ200878705 Available from: http://www.law.tulane.edu/uploadedfiles/WIPIP/2008/Galbraith_Abstract.docAccessed June 30, 2015
- AndandaPManaging intellectual property rights over clinical trial data to promote access and benefit sharing in public healthIIC2013442140177
- RoweEAStriking a balance: when should trade-secret law shield disclosures to the governmentIowa L Rev201096791
- WeissmanRPublic health-friendly options for protecting pharmaceutical registration dataIJIPM200611–2113130
- WeissmanRLong strange trips: the pharmaceutical industry drive to harmonize global intellectual property rules, and the remaining WTO legal alternatives available to third world countriesU Pa J Int’l Econ L1996171069
- GalantucciRData protection in a US-Malaysia free trade agreement: new barriers to market access for generic drug manufacturersFordham Intell Prop Media Ent L J2006171083 Available from: http://ir.lawnet.fordham.edu/cgi/viewcontent.cgi?article=1388&context=ipljAccessed June 30, 2015
- AbughanmSThe protection of pharmaceutical patents and data under TRIPS and US-Jordan FTA: exploring the limits of obligations and flexibilities: a study of the impacts on the pharmaceutical sector in JordanToronto, ONUniversity of Toronto20121618 Available from: http://hdl.handle.net/1807/32296Accessed June 30, 2015
- HoCAccess to medicine in the global economy: international agreements on patents and related rightsOxford, UKOxford University Press20114547
- BasheerSProtection of regulatory data under Article 39.3 of TRIPs: the Indian contextIntellectual Property Institute (IPI)2006 Available from SSRN: http://ssrn.com/abstract=934269Accessed June 30, 2015